PureTech Health plc (LON:PRTC - Get Free Report) reached a new 52-week low during trading on Thursday . The company traded as low as GBX 138 ($1.71) and last traded at GBX 143 ($1.77), with a volume of 1221521 shares trading hands. The stock had previously closed at GBX 140 ($1.73).
Separately, Jefferies Financial Group restated a "buy" rating and set a GBX 455 ($5.62) price objective on shares of PureTech Health in a research note on Monday, December 16th.
Check Out Our Latest Research Report on PRTC
The company has a debt-to-equity ratio of 47.27, a quick ratio of 2.51 and a current ratio of 3.68. The stock has a market cap of £342.37 million, a PE ratio of -621.74 and a beta of 1.02. The business has a 50 day moving average price of GBX 161.30 and a two-hundred day moving average price of GBX 162.91.
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.